BioInfra Co., Ltd. (KOSDAQ:199730)
South Korea · Delayed Price · Currency is KRW 1,510.00
-21.00 (-1.37%)
At close: Sep 3, 2026
BioInfra Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 25,623 | 23,148 | 23,833 | 30,129 | 35,427 | 30,555 |
Other Revenue | - | - | - | -0 | - | - |
| 25,623 | 23,148 | 23,833 | 30,129 | 35,427 | 30,555 | |
Revenue Growth | 4.69% | -2.88% | -20.89% | -14.96% | 15.95% | 55.82% |
Cost of Revenue | 19,170 | 17,918 | 18,233 | 20,656 | 21,529 | 18,576 |
Gross Profit | 6,453 | 5,230 | 5,600 | 9,472 | 13,898 | 11,979 |
Selling, General & Admin | 2,895 | 2,820 | 2,980 | 3,051 | 3,017 | 1,586 |
Research & Development | 8,211 | 8,010 | 6,960 | 4,488 | 4,006 | 2,781 |
Amortization of Goodwill & Intangibles | 121.56 | 127.04 | 128.57 | 115.41 | 81.23 | 37.22 |
Other Operating Expenses | 108.53 | 107.55 | 134.44 | 101.49 | 78.18 | 25.67 |
Operating Expenses | 11,740 | 11,507 | 10,717 | 8,167 | 7,538 | 4,517 |
Operating Income | -5,287 | -6,277 | -5,117 | 1,305 | 6,360 | 7,463 |
Interest Expense | -403.95 | -367.18 | -376.57 | -427.3 | -369.51 | -223.13 |
Interest & Investment Income | 170.26 | 253.51 | 405.25 | 366.75 | 50.48 | 47.27 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.6 | - | -55.96 | 6.76 |
Other Non Operating Income (Expenses) | -36.05 | -15.77 | -73.63 | 30.48 | 72.88 | -17.96 |
EBT Excluding Unusual Items | -5,557 | -6,406 | -5,161 | 1,275 | 6,058 | 7,276 |
Gain (Loss) on Sale of Investments | -1,660 | -1,701 | -714.52 | 3.33 | 24.79 | -209.88 |
Gain (Loss) on Sale of Assets | -17.3 | -17.3 | - | 0.05 | 903.7 | 33.04 |
Pretax Income | -7,234 | -8,125 | -5,876 | 1,279 | 6,987 | 7,099 |
Income Tax Expense | 1,053 | 1,006 | -1,900 | -723.09 | 749.37 | 864.63 |
Net Income | -8,287 | -9,131 | -3,976 | 2,002 | 6,237 | 6,234 |
Net Income to Common | -8,287 | -9,131 | -3,976 | 2,002 | 6,237 | 6,234 |
Net Income Growth | - | - | - | -67.91% | 0.05% | 48.75% |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 4 | 4 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 4 | 4 |
Shares Change | -0.04% | 0.32% | 3.20% | 13.83% | -0.02% | 200.05% |
EPS (Basic) | -1704.38 | -1877.13 | -820.00 | 426.00 | 1511.00 | 1510.00 |
EPS (Diluted) | -1704.38 | -1877.13 | -820.00 | 426.00 | 1511.00 | 1510.00 |
EPS Growth | - | - | - | -71.81% | 0.07% | -50.43% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2,504 | -2,824 | -1,071 | -2,395 | -2,107 | -7,559 |
Free Cash Flow Per Share | -514.91 | -580.50 | -220.92 | -509.75 | -510.36 | -1830.82 |
Gross Margin | 25.18% | 22.59% | 23.50% | 31.44% | 39.23% | 39.20% |
Operating Margin | -20.63% | -27.12% | -21.47% | 4.33% | 17.95% | 24.42% |
Profit Margin | -32.34% | -39.45% | -16.68% | 6.64% | 17.61% | 20.40% |
Free Cash Flow Margin | -9.77% | -12.20% | -4.49% | -7.95% | -5.95% | -24.74% |
EBITDA | -1,745 | -2,842 | -1,801 | 3,693 | 8,340 | 8,642 |
EBITDA Margin | -6.81% | -12.28% | -7.56% | 12.26% | 23.54% | 28.29% |
D&A For EBITDA | 3,542 | 3,435 | 3,316 | 2,388 | 1,980 | 1,180 |
EBIT | -5,287 | -6,277 | -5,117 | 1,305 | 6,360 | 7,463 |
EBIT Margin | -20.63% | -27.12% | -21.47% | 4.33% | 17.95% | 24.42% |
Effective Tax Rate | - | - | - | - | 10.73% | 12.18% |